A phase 1/2, first-in-human, multicenter, open-label trial evaluating the safety, tolerability, and antileukemic activity of Debio1562M in patients with recurrent refractory acute myeloid leukemia (AML)

Presented at The 67th ASH Annual Meeting

N. DAVER¹, A. SOCHACKI², M. AL MALKI³, E. WANG⁴, M. MULLER⁵, A. BELLON⁵, S. MICALLEF⁵, D. SALLMAN⁶ AND K. LARKIN⁷

1 MD Anderson Cancer Center, Houston, United States
2 South Texas Accelerated Research Therapeutics (start) Midwest, Grand Rapids, United States
3 City Of Hope National Medical Center, Duarte, United States
4 Roswell Park Comprehensive Cancer Center, Buffalo, United States
5 Debiopharm International SA, Lausanne, Switzerland
6 Moffitt Cancer Center, Tampa, United States
7 Ohio State University Hospital, Ohio, United States.